Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells

[1]  K. Bille,et al.  Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype , 2018, Genes & development.

[2]  A. Ganesan,et al.  Complete Acid Ceramidase ablation prevents cancer-initiating cell formation in melanoma cells , 2017, Scientific Reports.

[3]  K. Bille,et al.  Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression , 2017, Journal of the National Cancer Institute.

[4]  Jonathan L. Schmid-Burgk,et al.  MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. , 2017, Cancer research.

[5]  N. Haass,et al.  NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF , 2017, EBioMedicine.

[6]  Matthew J. Daniels,et al.  Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma , 2017, Genes & development.

[7]  A. Ganesan,et al.  Acid Ceramidase in Melanoma , 2015, The Journal of Biological Chemistry.

[8]  J. Landsberg,et al.  MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment , 2015, Nature Communications.

[9]  D. Gautheret,et al.  New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis , 2015, Cell reports.

[10]  D. Adams,et al.  Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts , 2015, EMBO molecular medicine.

[11]  S. Aerts,et al.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.

[12]  A. Weeraratna,et al.  Wnt5A promotes an adaptive, senescent‐like stress response, while continuing to drive invasion in melanoma cells , 2015, Pigment cell & melanoma research.

[13]  T. Fehm,et al.  Acid ceramidase is associated with an improved prognosis in both DCIS and invasive breast cancer , 2015, Molecular oncology.

[14]  T. Graeber,et al.  Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.

[15]  Y. Hannun,et al.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism. , 2014, Biochimica et biophysica acta.

[16]  Susanna Rossari,et al.  Discrepant alterations in main candidate genes among multiple primary melanomas , 2014, Journal of Translational Medicine.

[17]  J. Mesirov,et al.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.

[18]  A. Don,et al.  Re-Configuration of Sphingolipid Metabolism by Oncogenic Transformation , 2014, Biomolecules.

[19]  A. McKenna,et al.  Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy , 2013, Prostate Cancer and Prostatic Disease.

[20]  J. Geschwind,et al.  Tumor glycolysis as a target for cancer therapy: progress and prospects , 2013, Molecular Cancer.

[21]  Rajiv Narayan,et al.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.

[22]  J. Lachuer,et al.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. , 2013, Cancer cell.

[23]  A. Bielawska,et al.  Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. , 2013, The Journal of clinical investigation.

[24]  V. Bonazzi,et al.  Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype , 2013, Oncotarget.

[25]  Robert V Farese,et al.  Cellular fatty acid metabolism and cancer. , 2013, Cell metabolism.

[26]  P. Puigserver,et al.  PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.

[27]  Jun S. Song,et al.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. , 2013, Cancer cell.

[28]  V. Brunton,et al.  E-cadherin–integrin crosstalk in cancer invasion and metastasis , 2013, Journal of Cell Science.

[29]  S. Morad,et al.  Ceramide-orchestrated signalling in cancer cells , 2012, Nature Reviews Cancer.

[30]  T. Wieland,et al.  Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin αvβ5-induced secretion of VEGF-A. , 2012, The American journal of pathology.

[31]  E. Bertini,et al.  Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. , 2012, American journal of human genetics.

[32]  K. Bille,et al.  Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells* , 2012, The Journal of Biological Chemistry.

[33]  P. Bahadoran,et al.  Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells , 2012, Oncogene.

[34]  R. Dummer,et al.  Systematic classification of melanoma cells by phenotype‐specific gene expression mapping , 2012, Pigment cell & melanoma research.

[35]  K. Brown,et al.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.

[36]  S. Puig,et al.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.

[37]  K. Bille,et al.  Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). , 2011, Genes & development.

[38]  C. Bertolotto,et al.  Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma , 2011, Oncogene.

[39]  P. Bahadoran,et al.  Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny , 2011, Oncogene.

[40]  M. Sewer,et al.  Genistein Stimulates MCF-7 Breast Cancer Cell Growth by Inducing Acid Ceramidase (ASAH1) Gene Expression* , 2011, The Journal of Biological Chemistry.

[41]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[42]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[43]  Laurent Beuret,et al.  Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. , 2010, Cancer research.

[44]  C. Bertolotto,et al.  Fifteen‐year quest for microphthalmia‐associated transcription factor target genes , 2010, Pigment cell & melanoma research.

[45]  D. Metzler,et al.  Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer , 2009, Climacteric : the journal of the International Menopause Society.

[46]  E. Sahai,et al.  Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. , 2009, Cancer research.

[47]  M. Sewer,et al.  The cAMP-responsive element binding protein (CREB) regulates the expression of acid ceramidase (ASAH1) in H295R human adrenocortical cells. , 2009, Biochimica et biophysica acta.

[48]  S. Walkley,et al.  Secondary lipid accumulation in lysosomal disease. , 2009, Biochimica et biophysica acta.

[49]  A. Bielawska,et al.  Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  P. Nuciforo,et al.  Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. , 2008, Cancer research.

[51]  Jae-Ho Park,et al.  Autoproteolytic Cleavage and Activation of Human Acid Ceramidase* , 2008, Journal of Biological Chemistry.

[52]  P. V. van Diest,et al.  Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. , 2008, Biochemical and biophysical research communications.

[53]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[54]  A. Bielawska,et al.  Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  C. Bedia,et al.  Synthesis of a Novel Ceramide Analogue and its Use in a High‐Throughput Fluorogenic Assay for Ceramidases , 2007, Chembiochem : a European journal of chemical biology.

[56]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[57]  Jae-Ho Park,et al.  Acid ceramidase and human disease. , 2006, Biochimica et biophysica acta.

[58]  Jean-Philippe Brunet,et al.  The melanocyte differentiation program predisposes to metastasis after neoplastic transformation , 2005, Nature Genetics.

[59]  M. Khaled,et al.  The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. , 2005, Genes & development.

[60]  A. Merrill,et al.  Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. , 2005, Methods.

[61]  F. Lang,et al.  Human Acid Ceramidase , 2001, The Journal of Biological Chemistry.

[62]  S. Spiegel,et al.  Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors. , 1999, Cancer research.

[63]  O. Warburg.  On respiratory impairment in cancer cells. , 1956, Science.

[64]  C. Bertolotto,et al.  A germline oncogenic MITF mutation and tumor susceptibility. , 2014, European journal of cell biology.